Chugai Pharmaceutical will abolish the restricted stock compensation plan and introduce a trust-based stock compensation plan. Implementation is planned upon approval at the shareholders meeting on March 26, 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4519","jir_company_name":"Chugai Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-01-29","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/01\/4519-20260129-04.pdf","jir_short_summary":"Chugai Pharmaceutical will abolish the restricted stock compensation plan and introduce a trust-based stock compensation plan. Implementation is planned upon approval at the shareholders meeting on March 26, 2026.","jir_summary":"### Overview of Stock Compensation Plan Revision\nChugai Pharmaceutical Co., Ltd. has resolved to abolish the restricted stock compensation plan targeted at directors (excluding directors not engaged in business execution), executive officers, and employees, and to introduce a trust-based stock compensation plan. The same revision will be applied to directors and employees of subsidiaries, contingent on approval at the shareholders meeting scheduled for March 2026. The new plan will adopt two mechanisms: a BIP Trust for executives and an ESOP Trust for employees, aiming to enhance awareness of contributing to medium- to long-term corporate value growth.\n\n### Outlook and Impact on Shareholders\nWith the introduction of this plan, the existing restricted stock compensation plan will be abolished and no new restricted stock allocations will be made; however, already granted shares will continue to exist. Upon expiration of the trust period, new trusts will be established and existing trusts modified or supplemented to maintain continuous operation of the plan. A remuneration committee has been established to ensure transparency, and since implementation will occur following shareholders meeting approval, the impact on shareholders is expected to contribute positively to enhancing transparency and medium- to long-term corporate value.","jir_financial_highlights":"Abolition of Restricted Stock Compensation Plan: Unknown (The current plan will be abolished and transitioned to a new plan)\nIntroduction of Trust-Based Stock Compensation Plan: Unknown (New BIP Trust and ESOP Trust will be established)\nShareholders Meeting Date: 2026-03-26 (Date for approval of the new plan)","jir_category":"","jir_hashtags":"#ChugaiPharmaceuticalCoLtd, #StockCompensationPlanRevision, #StockOption","jir_key_figures":"Scheduled Shareholders Meeting Date: 2026-03-26 (115th Annual General Meeting)\nPlan Participants: Directors, Executive Officers, Employees of the Company and Directors and Employees of Subsidiaries\nNew Plan Names: BIP Trust (for Executives), ESOP Trust (for Employees)","jir_meta_title":"Chugai Pharmaceutical to Abolish Restricted Stock Compensation Plan and Seek Approval for Trust-Based Plan at March 2026 Shareholders Meeting","jir_meta_description":"Chugai Pharmaceutical will propose abolishing the restricted stock compensation plan and introducing a trust-based stock compensation plan at the shareholders meeting on March 26, 2026, promoting medium- to long-term corporate value contribution by executives and employees.","jir_og_title":"Chugai Pharmaceutical Revises Stock Compensation Plan to Trust-Based System","jir_og_description":"Chugai Pharmaceutical plans to abolish the restricted stock compensation plan and introduce a trust-based stock compensation plan, aiming for approval at the March 2026 shareholders meeting.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6836,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"stock_option","footnotes":""},"sector":[],"importance":[],"class_list":["post-21932","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n